

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA

**Rivaroxaban for the treatment of deep vein
thrombosis and prevention of recurrent deep vein
thrombosis and pulmonary embolism**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

During consultation on the scope, it was suggested that due consideration should be given to people who on religious or cultural values object to receiving porcine-derived heparin.

- | |
|---------------------------------------------------------------------------------------------------------------------|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---------------------------------------------------------------------------------------------------------------------|

The range of available products means that it was not considered that this needs to be addressed by the Committee.

- | |
|------------------------------------------------------------------------------------------|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|------------------------------------------------------------------------------------------|

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been added.

Approved by Associate Director (name):Janet Robertson.....

Date: 07 September 2011